Prana Receives Approval to Start Alzheimer's Trial
Posted on: Thursday, 5 October 2006, 12:00 CDT
Prana Biotechnology has received regulatory approval from Sweden's Medical Products Agency to start a phase IIa clinical trial of its lead compound, PBT2, in patients with early Alzheimer's disease.
The study, which will commence next month, will evaluate the safety and tolerability of PBT2. In addition, it will examine the drug's mechanism of action and indicators of potential efficacy in treating Alzheimer's disease.
Prana Biotechnology said that earlier clinical findings suggest that PBT2 may show biochemical and possibly cognitive benefit in the relatively short time frame in its phase IIa trial of mildly affected patients.
This trial forms part of Prana's strategy to assess the behavior of PBT2 across a broad dose range, in a manner that is also consistent with the new European Medicines Agency (EMEA) regulations that permit accelerated conditional marketing approval for treatments of seriously debilitating diseases such as Alzheimer's disease.
Results are expected to be announced in the fourth quarter of 2007.
Source: Datamonitor
Related Articles
- ANAVEX completes scale-up manufacturing of ANAVEX 2-73 for Phase I Alzheimer's disease clinical trials
- Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials
- Applied NeuroSolutions to Offer P-Tau 231 Test for Use in Alzheimer's Disease Clinical Trials
- ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimer's Disease
- Prana Completes Final Patient Dosing in Alzheimer's Phase II Trial
- Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease
- Research and Markets: 2007 Trial TRAX - Alzheimer's Disease - Clinical Trial Monitoring Brief Provides Detailed Compilations And Analysis Of Ongoing Studies
- Neurochem Reports on Alzheimer's Disease Drug Trial Results
- Medivation to Present Additional Alzheimer's Disease Data at BIO Investor Forum 2006
- Myriad Genetics Initiates Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
 |
 |
User Comments (0)
RSS Feeds